Form 4: Nutex Health COO Joshua DeTillio Acquires 63,750 Restricted Stock Units

Nutex Health's Chief Operating Officer, Joshua DeTillio, reports the acquisition of 63,750 Restricted Stock Units (RSUs) on June 28, 2024, which will vest in three equal installments.

Summary

• On June 28, 2024, Joshua DeTillio, the Chief Operating Officer of Nutex Health, Inc., acquired 63,750 Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of Nutex Health's common stock upon vesting.
• The RSUs will vest in three equal installments on March 1, 2025, March 1, 2026, and March 1, 2027, according to the Restricted Stock Unit Agreement.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of RSUs to the COO suggests confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of RSUs by a key executive like the COO can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the RSUs suggests a long-term commitment from the COO to the company's success.

Industry Context

This type of equity compensation is common in the healthcare industry to align management's interests with those of shareholders.

Comparison to Industry Standards

• Granting RSUs to key executives is a standard practice across publicly traded companies, including those in the healthcare sector like Universal Health Services and HCA Healthcare.
• The vesting schedule of three years is also typical, aligning with industry norms for executive compensation packages.

Stakeholder Impact

• The RSU grant aligns the COO's interests with those of shareholders, potentially driving long-term value creation.

Key Dates